Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human randomized study of AP31969 in healthy subjects
NL-OMON60309Phase 1Completed
- Sponsor
- Acesion Pharma
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of AP31969 in Atrial fibrillation (AFib) (2 arms), sponsored by Acesion Pharma. Started Oct 2023; status: completed.
02
Drugs
AP31969
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON60309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60309.